|Assessment Process Complete
|For the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. It is for use in the hospital setting.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not Recommended
The NCPE does not recommend reimbursement of radium-223 at the submitted price.
The HSE has approved reimbursement following confidential price negotiations December 2015.